Marian Case
Overview
Explore the profile of Marian Case including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
347
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Masic D, Fee K, Bell H, Case M, Witherington G, Lansbury S, et al.
Haematologica
. 2022 Nov;
108(4):981-992.
PMID: 36420798
Persistence of residual disease in acute lymphoblastic leukemia (ALL) during the initial stages of chemotherapy is associated with inferior survival. To better understand clonal evolution and mechanisms of chemoresistance, we...
2.
Doan M, Case M, Masic D, Hennig H, McQuin C, Caicedo J, et al.
Cytometry A
. 2020 Feb;
97(4):407-414.
PMID: 32091180
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. While there are a number of well-recognized prognostic biomarkers at diagnosis, the most powerful independent prognostic factor is the response...
3.
Sinclair P, Ryan S, Bashton M, Hollern S, Hanna R, Case M, et al.
Leukemia
. 2019 Mar;
33(8):1881-1894.
PMID: 30816328
In more than 30% of B-cell precursor acute lymphoblastic leukaemia (B-ALL), chromosome 21 sequence is overrepresented through aneuploidy or structural rearrangements, exemplified by intrachromosomal amplification of chromosome 21 (iAMP21). Although...
4.
Matheson E, Thomas H, Case M, Blair H, Jackson R, Masic D, et al.
Haematologica
. 2019 Jan;
104(9):1804-1811.
PMID: 30655370
New drugs are needed for the treatment of relapsed acute lymphoblastic leukemia and preclinical evaluation of the MEK inhibitor, selumetinib, has shown that this drug has excellent activity in those...
5.
Nicholson L, Evans C, Matheson E, Minto L, Keilty C, Sanichar M, et al.
Br J Haematol
. 2015 Aug;
171(4):595-605.
PMID: 26310606
Glucocorticoid (GC) resistance is a continuing clinical problem in childhood acute lymphoblastic leukaemia (ALL) but the underlying mechanisms remain unclear. A proteomic approach was used to compare profiles of the...
6.
Irving J, Matheson E, Minto L, Blair H, Case M, Halsey C, et al.
Blood
. 2014 Sep;
124(23):3420-30.
PMID: 25253770
For most children who relapse with acute lymphoblastic leukemia (ALL), the prognosis is poor, and there is a need for novel therapies to improve outcome. We screened samples from children...
7.
Nicholson L, Knight T, Matheson E, Minto L, Case M, Sanichar M, et al.
Genes Chromosomes Cancer
. 2011 Nov;
51(3):250-6.
PMID: 22072526
Casitas B-lineage lymphoma (CBL) proteins are RING finger ubiquitin E3 ligases that attenuate the signaling of receptor tyrosine kinases and are mutated in a number of myeloid disorders. In this...
8.
Wilson K, Case M, Minto L, Bailey S, Bown N, Jesson J, et al.
Haematologica
. 2009 Dec;
95(4):679-83.
PMID: 19951974
Flow cytometric minimal residual disease (MRD) monitoring could become more powerful if directed towards the disease-maintaining leukemic stem cell (LSC) compartment. Using a cohort of 48 children with B-lineage acute...
9.
Irving J, Jesson J, Virgo P, Case M, Minto L, Eyre L, et al.
Haematologica
. 2009 Apr;
94(6):870-4.
PMID: 19377076
Minimal residual disease detection, used for clinical management of children with acute lymphoblastic leukemia, can be performed by molecular analysis of antigen-receptor gene rearrangements or by flow cytometric analysis of...
10.
Parker H, An Q, Barber K, Case M, Davies T, Konn Z, et al.
Genes Chromosomes Cancer
. 2008 Sep;
47(12):1118-25.
PMID: 18767146
The ETV6-RUNX1 fusion is the molecular consequence of the t(12;21)(p13;q22) seen in approximately 25% of children with acute lymphoblastic leukemia (ALL). Studies have shown that the fusion alone is insufficient...